Journal article abstract here: https://www.nature.com/articles/s41569-025-01121-6
Video here: https://www.vumedi.com/video/the-relationship-between-cannabis-and-cardiovascular-disease/
Yikes.
coronary artery disease
ASCOT-Legacy 20-year follow-up – Long-term Benefits of Atorvastatin
Patients allocated to atorvastatin had a significant reduction in non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD) events (HR (95% CI) 0.81 (0.69 to 0.94, p=0.006)), total coronary events (0.88 (0.80 to 0.98, p=0.017)) and CV deaths (0.86 (0.74 to 0.99, p=0.048)). No significant reduction in heart failure (HF), strokes, total CV events and all-cause mortality was observed. Long-term benefits of atorvastatin on the incidence of cardiovascular events: the ASCOT-Legacy 20-year follow-up – https://heart.bmj.com/content/early/2025/03/25/heartjnl-2024-325104
Dr. M. Zann McMahan, thank you.
Rosuvastatin vs Atorvastatin in Adults with Coronary Artery Disease
In people with coronary artery disease, rosuvastatin and atorvastatin showed comparable efficacy in terms of a composite of all cause death, myocardial infarction, stroke, or any coronary revascularisation within three years
Rosuvastatin was associated with greater efficacy in reducing LDL cholesterol levels, but it incurred a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery than atorvastatin
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial – BMJ 2023;383:e075837 — https://doi.org/10.1136/bmj-2023-075837
lifeunderwriter.net 
You must be logged in to post a comment.